{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:05:08Z","timestamp":1791385508486,"version":"4.3.3"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T00:00:00Z","timestamp":1738540800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001077","name":"Royal Brisbane and Women's Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001704","name":"European Society of Clinical Microbiology and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ESCMID PK\/PD of Anti-Infectives Study Group"},{"name":"International Society of Antimicrobial Chemotherapy (ISAC) Infections in the ICU and Sepsis Working Group"},{"name":"Gilead Australia Fellowship","award":["14500"],"award-info":[{"award-number":["14500"]}]},{"DOI":"10.13039\/501100001794","name":"The University of Queensland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001794","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intensive Care Med"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00134-025-07793-5","type":"journal-article","created":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T11:32:29Z","timestamp":1738582349000},"page":"302-317","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Are contemporary antifungal doses sufficient for critically ill patients? Outcomes from an international, multicenter pharmacokinetics study for Screening Antifungal Exposure in Intensive Care Units\u2014the SAFE-ICU study"],"prefix":"10.1007","volume":"51","clinical-trial-number":[{"clinical-trial-number":"nct03136926","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade B.","family":"Sime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5965-9876","authenticated-orcid":false,"given":"Jeffrey","family":"Lipman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3565-0292","authenticated-orcid":false,"given":"Mar\u00eda Patricia","family":"Hern\u00e1ndez-Mitre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-806X","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Baptista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7618-725X","authenticated-orcid":false,"given":"Roger J.","family":"Br\u00fcggemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0579-8931","authenticated-orcid":false,"given":"Jai","family":"Darvall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1017-9748","authenticated-orcid":false,"given":"Jan J.","family":"De Waele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3784-3103","authenticated-orcid":false,"given":"George","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7774-2497","authenticated-orcid":false,"given":"Jean-Yves","family":"Lefrant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Basri","family":"Mat Nor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0676-6210","authenticated-orcid":false,"given":"Jordi","family":"Rello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9262-6673","authenticated-orcid":false,"given":"Leonardo","family":"Seoane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8443-314X","authenticated-orcid":false,"given":"Monica A.","family":"Slavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia","family":"Valkonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2639-0281","authenticated-orcid":false,"given":"Mario","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5921-3180","authenticated-orcid":false,"given":"Giancarlo","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Tat","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1873-3953","authenticated-orcid":false,"given":"Markus","family":"Zeitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6055-0034","authenticated-orcid":false,"given":"Claire","family":"Roger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,3]]},"reference":[{"key":"7793_CR1","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/nrdp.2018.27","volume":"373","author":"BJ Kullberg","year":"2015","unstructured":"Kullberg BJ, Arendrup MC (2015) Invasive candidiasis. Nat Rev Dis Prim 373:1445\u20131456. https:\/\/doi.org\/10.1038\/nrdp.2018.27","journal-title":"Nat Rev Dis Prim"},{"key":"7793_CR2","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1056\/nejmra2027424","volume":"385","author":"GR Thompson","year":"2021","unstructured":"Thompson GR, Young J-AH (2021) Aspergillus infections. N Engl J Med 385:1496\u20131509. https:\/\/doi.org\/10.1056\/nejmra2027424","journal-title":"N Engl J Med"},{"key":"7793_CR3","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/CCM.0000000000002210","volume":"45","author":"JA Roberts","year":"2017","unstructured":"Roberts JA, Kumar A, Lipman J (2017) Right dose, right now: customized drug dosing in the critically ill. Crit Care Med 45:331\u2013336. https:\/\/doi.org\/10.1097\/CCM.0000000000002210","journal-title":"Crit Care Med"},{"key":"7793_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","volume":"77","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J (2014) The effect of pathophysiology on pharmacokinetics in the critically ill patient - concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev 77:3\u201311. https:\/\/doi.org\/10.1016\/j.addr.2014.07.006","journal-title":"Adv Drug Deliv Rev"},{"key":"7793_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40262-023-01213-x","volume":"62","author":"D Morales Castro","year":"2023","unstructured":"Morales Castro D, Dresser L, Granton J, Fan E (2023) Pharmacokinetic alterations associated with critical illness. Clin Pharmacokinet 62:209\u2013220. https:\/\/doi.org\/10.1007\/s40262-023-01213-x","journal-title":"Clin Pharmacokinet"},{"key":"7793_CR6","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","volume":"46","author":"MH Abdul-Aziz","year":"2020","unstructured":"Abdul-Aziz MH, Alffenaar JWC, Bassetti M et al (2020) Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 46:1127\u20131153. https:\/\/doi.org\/10.1007\/s00134-020-06050-1","journal-title":"Intensive Care Med"},{"key":"7793_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR et al (2015) Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis 62:e1\u2013e50. https:\/\/doi.org\/10.1093\/cid\/civ933","journal-title":"Clin Infect Dis"},{"key":"7793_CR8","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","volume":"58","author":"JA Roberts","year":"2014","unstructured":"Roberts JA, Paul SK, Akova M et al (2014) DALI: Defining antibiotic levels in intensive care unit patients: are current \u00df-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis 58:1072\u20131083. https:\/\/doi.org\/10.1093\/cid\/ciu027","journal-title":"Clin Infect Dis"},{"key":"7793_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-015-0758-3","volume":"19","author":"MG Sinnollareddy","year":"2015","unstructured":"Sinnollareddy MG, Roberts JA, Lipman J et al (2015) Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: data from multinational defining antibiotic levels in intensive care unit (DALI) patients study. Crit Care 19:1\u20137. https:\/\/doi.org\/10.1186\/s13054-015-0758-3","journal-title":"Crit Care"},{"key":"7793_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ccrj.2023.04.002","volume":"25","author":"JA Roberts","year":"2023","unstructured":"Roberts JA, Sime F, Lipman J et al (2023) A protocol for an international, multicentre pharmacokinetic study for Screening Antifungal Exposure in Intensive Care Units: the SAFE-ICU study. Crit Care Resusc 25:1\u20135. https:\/\/doi.org\/10.1016\/j.ccrj.2023.04.002","journal-title":"Crit Care Resusc"},{"key":"7793_CR11","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (2022) M10 Bioanalytical Method Validation and Study Sample Analysis. Guidance for Industry"},{"key":"7793_CR12","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4027011\/v1","author":"M Mart\u00edn-Cerezuela","year":"2024","unstructured":"Mart\u00edn-Cerezuela M, Maya-Gallegos C, Marqu\u00e9s Mi\u00f1ana M et al (2024) Isavuconazole pharmacokinetics in critically ill patients: relationship with clinical effectiveness and patient safety. Res Sq. https:\/\/doi.org\/10.21203\/rs.3.rs-4027011\/v1","journal-title":"Res Sq"},{"key":"7793_CR13","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1093\/jac\/dkz188","volume":"74","author":"E Furfaro","year":"2019","unstructured":"Furfaro E, Signori A, Di Grazia C et al (2019) Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. J Antimicrob Chemother 74:2341\u20132346. https:\/\/doi.org\/10.1093\/jac\/dkz188","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR14","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1128\/AAC.01584-09","volume":"54","author":"D Andes","year":"2010","unstructured":"Andes D, Diekema DJ, Pfaller MA et al (2010) In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob Agents Chemother 54:2497\u20132506. https:\/\/doi.org\/10.1128\/AAC.01584-09","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01477-16","volume":"61","author":"NL Seibel","year":"2017","unstructured":"Seibel NL, Shad AT, Bekersky I et al (2017) Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients. Antimicrob Agents Chemother 61:1\u201311","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR16","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.cmi.2020.05.037","volume":"26","author":"A G\u00f3mez-L\u00f3pez","year":"2020","unstructured":"G\u00f3mez-L\u00f3pez A (2020) Antifungal therapeutic drug monitoring: focus on drugs without a clear recommendation. Clin Microbiol Infect 26:1481\u20131487. https:\/\/doi.org\/10.1016\/j.cmi.2020.05.037","journal-title":"Clin Microbiol Infect"},{"key":"7793_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1128\/AAC.01607-13","volume":"58","author":"MJP van Wanrooy","year":"2014","unstructured":"van Wanrooy MJP, Rodgers MGG, Uges DRA et al (2014) Low but sufficient anidulafungin exposure in critically ill patients. Antimicrob Agents Chemother 58:304\u2013308. https:\/\/doi.org\/10.1128\/AAC.01607-13","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01894-16","volume":"61","author":"RJM Br\u00fcggemann","year":"2017","unstructured":"Br\u00fcggemann RJM, Middel-Baars V, De Lange DW et al (2017) Pharmacokinetics of anidulafungin in critically ill intensive care unit patients with suspected or proven invasive fungal infections. Antimicrob Agents Chemother 61:1\u20138. https:\/\/doi.org\/10.1128\/AAC.01894-16","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR19","first-page":"1","volume":"61","author":"KCM van der Elst","year":"2017","unstructured":"van der Elst KCM, Veringa A, Zijlstra JG et al (2017) Low caspofungin exposure in patients in intensive care units. Antimicrob Agents Chemother 61:1\u201310","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.02466-18","volume":"63","author":"S Kurland","year":"2019","unstructured":"Kurland S, Furebring M, L\u00f6wdin E et al (2019) Pharmacokinetics of caspofungin in critically ill patients in relation to liver dysfunction: differential impact of plasma albumin and bilirubin levels. Antimicrob Agents Chemother 63:1\u201311. https:\/\/doi.org\/10.1128\/AAC.02466-18","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01398-17","volume":"61","author":"JM Boonstra","year":"2017","unstructured":"Boonstra JM, Van Der Elst KC, Veringa A et al (2017) Pharmacokinetic properties of micafungin in critically ill patients diagnosed with invasive candidiasis. Antimicrob Agents Chemother 61:1\u201311. https:\/\/doi.org\/10.1128\/AAC.01398-17","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/jac\/dkw352","volume":"72","author":"V Jullien","year":"2017","unstructured":"Jullien V, Azoulay E, Schwebel C et al (2017) Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 72:181\u2013189. https:\/\/doi.org\/10.1093\/jac\/dkw352","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR23","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1093\/jac\/dkv173","volume":"70","author":"S Grau","year":"2015","unstructured":"Grau S, Luque S, Campillo N et al (2015) Plasma and peritoneal fluid population pharmacokinetics of micafungin in post-surgical patients with severe peritonitis. J Antimicrob Chemother 70:2854\u20132861. https:\/\/doi.org\/10.1093\/jac\/dkv173","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR24","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1111\/jphp.13353","volume":"72","author":"I Kapralos","year":"2020","unstructured":"Kapralos I, Mainas E, Neroutsos E et al (2020) Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose? J Pharm Pharmacol 72:1750\u20131760. https:\/\/doi.org\/10.1111\/jphp.13353","journal-title":"J Pharm Pharmacol"},{"key":"7793_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-021-01062-6","volume":"65","author":"N Garbez","year":"2021","unstructured":"Garbez N, Mbatchi LC, Wallis SC et al (2021) Prospective cohort study of micafungin population pharmacokinetic analysis in plasma and peritoneal fluid in septic patients with intra-abdominal infections. Clin Pharmacokinet 65:1\u201313. https:\/\/doi.org\/10.1007\/s40262-021-01062-6","journal-title":"Clin Pharmacokinet"},{"key":"7793_CR26","doi-asserted-by":"publisher","first-page":"4403","DOI":"10.1128\/AAC.00623-15","volume":"59","author":"VJ Lempers","year":"2015","unstructured":"Lempers VJ, Schouten JA, Hunfeld NG et al (2015) Altered micafungin pharmacokinetics in intensive care unit patients. Antimicrob Agents Chemother 59:4403\u20134409. https:\/\/doi.org\/10.1128\/AAC.00623-15","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR27","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/FTD.0b013e31821fb197","volume":"33","author":"J Ray","year":"2011","unstructured":"Ray J, Campbell L, Rudham S et al (2011) Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit 33:387\u2013392. https:\/\/doi.org\/10.1097\/FTD.0b013e31821fb197","journal-title":"Ther Drug Monit"},{"key":"7793_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00242-18","volume":"62","author":"FB Sime","year":"2018","unstructured":"Sime FB, Stuart J, Butler J et al (2018) Pharmacokinetics of intravenous posaconazole in critically Ill patients. Antimicrob Agents Chemother 62:1\u20137. https:\/\/doi.org\/10.1128\/AAC.00242-18","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR29","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jac\/dkae037","volume":"79","author":"M Mikulska","year":"2024","unstructured":"Mikulska M, Melchio M, Signori A et al (2024) Lower blood levels of isavuconazole in critically ill patients compared with other populations: possible need for therapeutic drug monitoring. J Antimicrob Chemother 79:835\u2013845. https:\/\/doi.org\/10.1093\/jac\/dkae037","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics12071085","volume":"12","author":"B Mertens","year":"2023","unstructured":"Mertens B, Elkayal O, Dreesen E et al (2023) Isavuconazole exposure in critically ill patients treated with extracorporeal membrane oxygenation: two case reports and a narrative literature review. Antibiotics 12:1\u201319. https:\/\/doi.org\/10.3390\/antibiotics12071085","journal-title":"Antibiotics"},{"key":"7793_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01554-20","volume":"65","author":"JM Boonstra","year":"2021","unstructured":"Boonstra JM, M\u00e4rtson AG, Sandaradura I et al (2021) Optimization of fluconazole dosing for the prevention and treatment of invasive candidiasis based on the pharmacokinetics of fluconazole in critically ill patients. Antimicrob Agents Chemother 65:1\u201311. https:\/\/doi.org\/10.1128\/AAC.01554-20","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9102068","volume":"9","author":"R Van Daele","year":"2021","unstructured":"Van Daele R, Wauters J, Lagrou K et al (2021) Pharmacokinetic variability and target attainment of fluconazole in critically ill patients. Microorganisms 9:1\u201312. https:\/\/doi.org\/10.3390\/microorganisms9102068","journal-title":"Microorganisms"},{"key":"7793_CR33","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.idnow.2022.10.002","volume":"53","author":"AL Bienvenu","year":"2023","unstructured":"Bienvenu AL, Pradat P, Matusik E et al (2023) Suboptimal exposure to fluconazole in critically ill patients: pharmacokinetic analysis and determinants. Infect Dis Now 53:2\u20134. https:\/\/doi.org\/10.1016\/j.idnow.2022.10.002","journal-title":"Infect Dis Now"},{"key":"7793_CR34","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1164\/rccm.202207-1393OC","volume":"207","author":"K Shekar","year":"2023","unstructured":"Shekar K, Abdul-Aziz MH, Cheng V et al (2023) Antimicrobial exposures in critically ill patients receiving extracorporeal membrane oxygenation. Am J Respir Crit Care Med 207:704\u2013720. https:\/\/doi.org\/10.1164\/rccm.202207-1393OC","journal-title":"Am J Respir Crit Care Med"},{"key":"7793_CR35","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1128\/AAC.02139-12","volume":"57","author":"P Liu","year":"2013","unstructured":"Liu P, Ruhnke M, Meersseman W et al (2013) Pharmacokinetics of anidulafungin in critically ill patients with candidemia\/invasive candidiasis. Antimicrob Agents Chemother 57:1672\u20131676. https:\/\/doi.org\/10.1128\/AAC.02139-12","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR36","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1111\/bcp.14457","volume":"87","author":"I Kapralos","year":"2021","unstructured":"Kapralos I, Mainas E, Apostolopoulou O et al (2021) Population pharmacokinetics of anidulafungin in ICU patients assessing inter- and intrasubject variability. Br J Clin Pharmacol 87:1024\u20131032. https:\/\/doi.org\/10.1111\/bcp.14457","journal-title":"Br J Clin Pharmacol"},{"key":"7793_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1093\/jac\/dkm125","volume":"60","author":"TH Nguyen","year":"2007","unstructured":"Nguyen TH, Hoppe-Tichy T, Geiss HK et al (2007) Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 60:100\u2013106. https:\/\/doi.org\/10.1093\/jac\/dkm125","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR38","doi-asserted-by":"publisher","first-page":"3294","DOI":"10.1093\/jac\/dku313","volume":"69","author":"EW Muilwijk","year":"2014","unstructured":"Muilwijk EW, Schouten JA, van Leeuwen HJ et al (2014) Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother 69:3294\u20133299. https:\/\/doi.org\/10.1093\/jac\/dku313","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s40262-015-0347-2","volume":"55","author":"LC Martial","year":"2016","unstructured":"Martial LC, Br\u00fcggemann RJM, Schouten JA et al (2016) Dose reduction of caspofungin in intensive care unit patients with Child Pugh B will result in suboptimal exposure. Clin Pharmacokinet 55:723\u2013733. https:\/\/doi.org\/10.1007\/s40262-015-0347-2","journal-title":"Clin Pharmacokinet"},{"key":"7793_CR40","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01545-20","author":"S Bailly","year":"2020","unstructured":"Bailly S, Gautier-Veyret E, L\u00ea MP et al (2020) Impact of loading dose of caspofungin in pharmacokinetic-pharmacodynamic target attainment for severe candidiasis infections in patients in intensive care units: the CASPOLOAD study. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/AAC.01545-20","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR41","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1080\/1120009X.2020.1737783","volume":"32","author":"C Adembri","year":"2020","unstructured":"Adembri C, Villa G, Rosi E et al (2020) Caspofungin PK in critically ill patients after the first and fourth doses: suggestions for therapeutic drug monitoring? J Chemother 32:124\u2013131. https:\/\/doi.org\/10.1080\/1120009X.2020.1737783","journal-title":"J Chemother"},{"key":"7793_CR42","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1128\/aac.41.6.1275","volume":"41","author":"V Heinemann","year":"1997","unstructured":"Heinemann V, Bosse D, Jehn U et al (1997) Pharmacokinetics of liposomal amphotericin B (AmBisome) in critically ill patients. Antimicrob Agents Chemother 41:1275\u20131280. https:\/\/doi.org\/10.1128\/aac.41.6.1275","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/mmy\/myac074","volume":"60","author":"R Van Daele","year":"2022","unstructured":"Van Daele R, Wauters J, Elkayal O et al (2022) Liposomal amphotericin B exposure in critically ill patients: a prospective pharmacokinetic study. Med Mycol 60:1\u20138. https:\/\/doi.org\/10.1093\/mmy\/myac074","journal-title":"Med Mycol"},{"key":"7793_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1093\/jac\/dkac389","volume":"78","author":"KE Stott","year":"2023","unstructured":"Stott KE, Moyo M, Ahmadu A et al (2023) Population pharmacokinetics of liposomal amphotericin B in adults with HIV-associated cryptococcal meningoencephalitis. J Antimicrob Chemother 78:276\u2013283. https:\/\/doi.org\/10.1093\/jac\/dkac389","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/microorganisms9102087","volume":"9","author":"J Grensemann","year":"2021","unstructured":"Grensemann J, Pfaffendorf C, Wicha SG et al (2021) Voriconazole pharmacokinetics are not altered in critically ill patients with acute-on-chronic liver failure and continuous renal replacement therapy: an observational study. Microorganisms 9:1\u201313. https:\/\/doi.org\/10.3390\/microorganisms9102087","journal-title":"Microorganisms"},{"key":"7793_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/FTD.0000000000000284","volume":"38","author":"MJP Van Wanrooy","year":"2016","unstructured":"Van Wanrooy MJP, Rodgers MGG, Span LFR et al (2016) Voriconazole therapeutic drug monitoring practices in intensive care. Ther Drug Monit 38:313\u2013318. https:\/\/doi.org\/10.1097\/FTD.0000000000000284","journal-title":"Ther Drug Monit"},{"key":"7793_CR47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/jcpt.12817","volume":"44","author":"J Ruiz","year":"2019","unstructured":"Ruiz J, Gordon M, Villarreal E et al (2019) Impact of voriconazole plasma concentrations on treatment response in critically ill patients. J Clin Pharm Ther 44:572\u2013578. https:\/\/doi.org\/10.1111\/jcpt.12817","journal-title":"J Clin Pharm Ther"},{"key":"7793_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/antibiotics9090574","volume":"9","author":"B Khan-Asa","year":"2020","unstructured":"Khan-Asa B, Punyawudho B, Singkham N et al (2020) Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases. Antibiotics 9:1\u201314. https:\/\/doi.org\/10.3390\/antibiotics9090574","journal-title":"Antibiotics"},{"key":"7793_CR49","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","volume":"35","author":"P Myrianthefs","year":"2010","unstructured":"Myrianthefs P, Markantonis SL, Evaggelopoulou P et al (2010) Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study. Int J Antimicrob Agents 35:468\u2013472. https:\/\/doi.org\/10.1016\/j.ijantimicag.2009.12.021","journal-title":"Int J Antimicrob Agents"},{"key":"7793_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2022.106692","volume":"60","author":"T Wang","year":"2022","unstructured":"Wang T, Miao L, Shao H et al (2022) Voriconazole therapeutic drug monitoring and hepatotoxicity in critically ill patients: a nationwide multi-centre retrospective study. Int J Antimicrob Agents 60:1\u20139. https:\/\/doi.org\/10.1016\/j.ijantimicag.2022.106692","journal-title":"Int J Antimicrob Agents"},{"key":"7793_CR51","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1007\/s15010-023-02078-9","volume":"51","author":"C K\u00f6nig","year":"2023","unstructured":"K\u00f6nig C, G\u00f6pfert M, Kluge S, Wichmann D (2023) Posaconazole exposure in critically ill ICU patients: a need for action. Infection 51:1767\u20131772. https:\/\/doi.org\/10.1007\/s15010-023-02078-9","journal-title":"Infection"},{"key":"7793_CR52","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1111\/myc.13446","volume":"65","author":"R Van Daele","year":"2022","unstructured":"Van Daele R, Wauters J, Dreesen E et al (2022) Exposure to intravenous posaconazole in critically ill patients with influenza: a pharmacokinetic analysis of the POSA-FLU study. Mycoses 65:656\u2013660. https:\/\/doi.org\/10.1111\/myc.13446","journal-title":"Mycoses"},{"key":"7793_CR53","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1007\/s10096-021-04201-w","volume":"40","author":"I Sandaradura","year":"2021","unstructured":"Sandaradura I, Marriott DJE, Day RO et al (2021) Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. Eur J Clin Microbiol Infect Dis 40:1521\u20131528. https:\/\/doi.org\/10.1007\/s10096-021-04201-w","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"7793_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00984-20","volume":"64","author":"EW Muilwijk","year":"2020","unstructured":"Muilwijk EW, de Lange DW, Schouten JA et al (2020) Suboptimal dosing of fluconazole in critically ill patients: time to rethink dosing. Antimicrob Agents Chemother 64:1\u20136","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR55","doi-asserted-by":"publisher","first-page":"5868","DOI":"10.1128\/AAC.00424-11","volume":"55","author":"K Patel","year":"2011","unstructured":"Patel K, Roberts JA, Lipman J et al (2011) Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 55:5868\u20135873. https:\/\/doi.org\/10.1128\/AAC.00424-11","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.01201-23","volume":"68","author":"E Novy","year":"2024","unstructured":"Novy E, Abdul-Aziz MH, Cheng V et al (2024) Population pharmacokinetics of fluconazolein critically ill patients receiving extracorporeal membrane oxygenation and continuous renal replacement therapy: an ASAP ECMO study. Antimicrob Agents Chemother 68:1\u201313. https:\/\/doi.org\/10.1128\/aac.01201-23","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12941-017-0235-8","volume":"16","author":"WM Yi","year":"2017","unstructured":"Yi WM, Schoeppler KE, Jaeger J et al (2017) Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study. Ann Clin Microbiol Antimicrob 16:1\u201314. https:\/\/doi.org\/10.1186\/s12941-017-0235-8","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"7793_CR58","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1111\/bcpt.13465","volume":"127","author":"H Li","year":"2020","unstructured":"Li H, Li M, Yan J et al (2020) Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy. Basic Clin Pharmacol Toxicol 127:495\u2013504. https:\/\/doi.org\/10.1111\/bcpt.13465","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"7793_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0260656","volume":"16","author":"AL Bienvenu","year":"2021","unstructured":"Bienvenu AL, Pradat P, Plesa A et al (2021) Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients. PLoS ONE 16:1\u201311. https:\/\/doi.org\/10.1371\/journal.pone.0260656","journal-title":"PLoS ONE"},{"key":"7793_CR60","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bcp.14953","volume":"88","author":"P Bakir Ekinci","year":"2022","unstructured":"Bakir Ekinci P, Kara E, Er AG et al (2022) Challenge in treating COVID-19 associate pulmonary aspergillosis: supratherapeutic voriconazole levels. Br J Clin Pharmacol 88:1387\u20131391. https:\/\/doi.org\/10.1111\/bcp.14953","journal-title":"Br J Clin Pharmacol"},{"key":"7793_CR61","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/jcpt.13518","volume":"47","author":"P Mian","year":"2022","unstructured":"Mian P, Trof RJ, Beishuizen A et al (2022) Suboptimal plasma concentrations with posaconazole suspension as prophylaxis in critically ill COVID-19 patients at risk of Covid-associated pulmonary aspergillosis. J Clin Pharm Ther 47:383\u2013385. https:\/\/doi.org\/10.1111\/jcpt.13518","journal-title":"J Clin Pharm Ther"},{"key":"7793_CR62","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"L Chen","year":"2020","unstructured":"Chen L, Krekels EHJ, Verweij PE et al (2020) Pharmacokinetics and pharmacodynamics of posaconazole. Drugs 80:671\u2013695. https:\/\/doi.org\/10.1007\/s40265-020-01306-y","journal-title":"Drugs"},{"key":"7793_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13122099","volume":"13","author":"PG Cojutti","year":"2021","unstructured":"Cojutti PG, Carnelutti A, Lazzarotto D et al (2021) Population pharmacokinetics and pharmacodynamic target attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as. Pharmaceutics 13:1\u201313. https:\/\/doi.org\/10.3390\/pharmaceutics13122099","journal-title":"Pharmaceutics"},{"key":"7793_CR64","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1111\/myc.13469","volume":"65","author":"R H\u00f6hl","year":"2022","unstructured":"H\u00f6hl R, Bertram R, Kinzig M et al (2022) Isavuconazole therapeutic drug monitoring in critically ill ICU patients: a monocentric retrospective analysis. Mycoses 65:747\u2013752. https:\/\/doi.org\/10.1111\/myc.13469","journal-title":"Mycoses"},{"key":"7793_CR65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/jof9020211","volume":"9","author":"L Perez","year":"2023","unstructured":"Perez L, Corne P, Pasquier G et al (2023) Population pharmacokinetics of isavuconazole in critical care patients with COVID-19-associated pulmonary aspergillosis and Monte Carlo simulations of high off-label doses. J Fungi 9:2\u201317. https:\/\/doi.org\/10.3390\/jof9020211","journal-title":"J Fungi"},{"key":"7793_CR66","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s40262-023-01305-8","volume":"62","author":"AME Jansen","year":"2023","unstructured":"Jansen AME, Mertens B, Spriet I et al (2023) Population pharmacokinetics of total and unbound isavuconazole in critically ill patients: implications for adaptive dosing strategies. Clin Pharmacokinet 62:1701\u20131711. https:\/\/doi.org\/10.1007\/s40262-023-01305-8","journal-title":"Clin Pharmacokinet"},{"key":"7793_CR67","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1093\/jac\/dkt542","volume":"69","author":"G Aguilar","year":"2014","unstructured":"Aguilar G, Azanza JR, Carbonell JA et al (2014) Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration. J Antimicrob Chemother 69:1620\u20131623. https:\/\/doi.org\/10.1093\/jac\/dkt542","journal-title":"J Antimicrob Chemother"},{"key":"7793_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00378-19","volume":"63","author":"S Luque","year":"2019","unstructured":"Luque S, Hope W, Campillo N et al (2019) Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrob Agents Chemother 63:1\u20135. https:\/\/doi.org\/10.1128\/AAC.00378-19","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00905-20","volume":"64","author":"AG M\u00e4rtson","year":"2020","unstructured":"M\u00e4rtson AG, van der Elst KCM, Veringa A et al (2020) Caspofungin weight-based dosing supported by a population pharmacokinetic model in critically ill patients. Antimicrob Agents Chemother 64:1\u201310. https:\/\/doi.org\/10.1128\/AAC.00905-20","journal-title":"Antimicrob Agents Chemother"},{"key":"7793_CR70","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jgar.2021.03.011","volume":"25","author":"F Li","year":"2021","unstructured":"Li F, Zhou M, Jiao Z et al (2021) Caspofungin pharmacokinetics and probability of target attainment in ICU patients in China. J Glob Antimicrob Resist 25:238\u2013263. https:\/\/doi.org\/10.1016\/j.jgar.2021.03.011","journal-title":"J Glob Antimicrob Resist"},{"key":"7793_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-018-2019-8","volume":"22","author":"E Maseda","year":"2018","unstructured":"Maseda E, Grau S, Luque S et al (2018) Population pharmacokinetics\/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients. Crit Care 22:1\u20139. https:\/\/doi.org\/10.1186\/s13054-018-2019-8","journal-title":"Crit Care"},{"key":"7793_CR72","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.medmal.2018.10.011","volume":"49","author":"JB Foulquier","year":"2019","unstructured":"Foulquier JB, Berneau P, Fr\u00e9rou A et al (2019) Liposomal amphotericin B pharmacokinetics in a patient treated with extracorporeal membrane oxygenation. Med Mal Infect 49:69\u201371. https:\/\/doi.org\/10.1016\/j.medmal.2018.10.011","journal-title":"Med Mal Infect"},{"key":"7793_CR73","first-page":"360","volume":"26","author":"F \u00c1lvarez-Lerma","year":"2013","unstructured":"\u00c1lvarez-Lerma F, Rodriguez M, Soriano MC et al (2013) Effectiveness of liposomal amphotericin B in patients admitted to the ICU on renal replacement therapy. Rev Esp Quimioter 26:360\u2013368","journal-title":"Rev Esp Quimioter"}],"container-title":["Intensive Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00134-025-07793-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00134-025-07793-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:31:48Z","timestamp":1741793508000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00134-025-07793-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7793"],"URL":"https:\/\/doi.org\/10.1007\/s00134-025-07793-5","relation":{},"ISSN":["0342-4642","1432-1238"],"issn-type":[{"value":"0342-4642","type":"print"},{"value":"1432-1238","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JA Roberts has consulted or provided lectures for Qpex, Gilead, Advanz Pharma, Sandoz, Pfizer, MSD, Gilead and Cipla. JJ De Waele has consulted for Biomerieux, Menarini, Monlycke, MSD, Pfizer, Roche Diagnostics, ThermoFisher and Viatris (fees and honoraria paid to institution).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}